Prostate Cancer - Results from #2040

A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities. October 9, 2023

Study of prostate-specific antigen levels during salvage radiotherapy after prostate cancer surgery. October 9, 2023

Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer. October 9, 2023

Statins may increase the risk of being diagnosed with prostate cancer. October 9, 2023

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy? October 9, 2023

Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer. October 6, 2023

Tandem Isotope Therapy with 225Ac- and 177Lu-PSMA-617 in a Murine Model of Prostate Cancer. October 6, 2023

Prognostic factors for mental wellbeing in prostate cancer: A systematic review and meta-analysis. October 6, 2023

Testosterone as a Biomarker for Quality of Life (QOL) Following Androgen Deprivation Therapy (ADT) and Stereotactic Body Radiotherapy (SBRT). October 6, 2023

An Actionable Expert-System Algorithm to Support Nurse-Led Cancer Survivorship Care: Algorithm Development Study. October 6, 2023

Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial. October 6, 2023

Long-Term Outcomes Following Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy in High-Risk Prostate Cancer: Update From the FASTR/FASTR-2 Trials. October 6, 2023

Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. October 6, 2023

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. October 5, 2023

Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy. October 5, 2023

Identifying proteomic risk factors for overall, aggressive and early onset prostate cancer using Mendelian randomization and tumor spatial transcriptomics. October 5, 2023

Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial. October 5, 2023

Spatial transcriptomic analysis of virtual prostate biopsy reveals confounding effect of tissue heterogeneity on genomic signatures. October 5, 2023

Age 70 +/- 5 Years and Cancer Specific Outcomes after Treatment of Localized Prostate Cancer: A Systematic Review. October 5, 2023

Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer. October 4, 2023

Page 103 of 1439